Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 17, 2026

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

8.9K

Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy?

Kegan Jessamy1, Fidelis O Ojevwe1, Ravi Doobay1

  • 1Department of Medicine, SUNY Upstate Medical University, Syracuse, N.Y., USA.

Case Reports in Oncology
|July 28, 2016
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancements in extracellular vesicle research.

Extracellular vesicle·2026
Same author

The utility of clonal relatedness molecular testing in cytology: An institutional experience.

Annals of diagnostic pathology·2026
Same author

Desquamating Esophagitis in the Era of Immune Checkpoint Inhibitors: A Rare Upper Gastrointestinal Manifestation.

ACG case reports journal·2026
Same author

Intramuscular myxoma with chondroid features: two cases expanding the morphological spectrum.

Histopathology·2026
Same author

Epithelioid Fibrous Histiocytoma With an <i>ETV6::NTRK3</i> Fusion in a Child: A Case Expanding the Spectrum of Receptor-Tyrosine Kinase Driven Epithelioid Fibrous Histiocytoma.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·2026
Same author

DAB2IP modulates intestinal inflammation by enhancing ILC3 function in the gut.

Journal of immunology (Baltimore, Md. : 1950)·2026

Primary effusion lymphoma (PEL), a rare cancer in HIV patients, typically affects body cavities. Chemotherapy, such as dose-adjusted EPOCH, shows promise in improving survival rates for this aggressive lymphoma.

Area of Science:

  • Oncology
  • Virology
  • Hematology

Background:

  • Primary effusion lymphoma (PEL) is a rare, aggressive non-Hodgkin lymphoma.
  • PEL is strongly associated with human immunodeficiency virus (HIV) infection, accounting for approximately 4% of HIV-associated lymphomas.
  • This lymphoma characteristically involves body cavities, including the pleural, pericardial, and peritoneal spaces.

Observation:

  • A case study of a 47-year-old male with HIV and Kaposi's sarcoma presenting with abdominal pain and distension is detailed.
  • The patient was diagnosed with primary effusion lymphoma.
  • Clinical data for PEL is often limited, highlighting the importance of case reports.

Findings:

  • Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) chemotherapy has demonstrated efficacy in treating PEL.
Keywords:
Acquired immunodeficiency syndromeDose-adjusted EPOCHEPOCHHuman immunodeficiency virusKaposi's sarcomaPrimary effusion lymphoma

More Related Videos

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.8K

Related Experiment Videos

Last Updated: Mar 17, 2026

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

8.9K
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.8K
  • Chemotherapy significantly improves median survival rates compared to no treatment.
  • While median survival is short (2-3 months without treatment, ~6 months with chemotherapy), EPOCH offers a potential survival benefit.

    • Implications:

    • This case underscores the importance of considering PEL in HIV-positive individuals with unexplained effusions or abdominal symptoms.
    • Dose-adjusted EPOCH chemotherapy represents a viable treatment option for improving outcomes in PEL.
    • Further research is warranted to optimize treatment strategies and improve long-term survival for patients with primary effusion lymphoma.